SCHEMBL2676756

SCHEMBL2676756

Cc1nc(Cl)ccc1OC(CC1CCC1)C1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SSTR4 P31391 1/20 0.39
▸ GPR119 Q8TDV5 5/20 0.37
▸ TP53 P04637 1/20 0.37
▸ PDE4B Q07343 1/20 0.37
▸ TRPV3 Q8NET8 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ ACKR3 P25106 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ USP30 Q70CQ3 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL586400 0.96 SSTR4 (0.40) SSTR4GPR119TP53PDE4BALDH1A1
SCHEMBL10090874 0.87 SLC6A2 (0.41) SSTR4GPR119TP53TRPV3ALDH1A1
SCHEMBL590425 0.87 SLC6A2 (0.41) SSTR4GPR119TP53TRPV3ALDH1A1
SCHEMBL2675147 0.85 SSTR4 (0.41) SSTR4GPR119TP53PDE4BTRPV3
SCHEMBL10090902 0.83 SSTR4 (0.37) SSTR4GPR119
SCHEMBL26180110 0.76 PIK3CD (0.48) SSTR4GPR119PDE4BPDE4D
SCHEMBL590981 0.76 SLC6A2 (0.55) GPR119PDE4BALDH1A1KDM4EHPGD
SCHEMBL592676 0.75 GPR119 (0.41) GPR119PDE4BTRPV3ALDH1A1MEN1
SCHEMBL586621 0.75 SLC6A2 (0.45) GPR119HPGDNPSR1
SCHEMBL10090887 0.74 SLC6A2 (0.40) SSTR4GPR119KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173821-B2 Serotonin and norepinephrine reuptake inhibitor ELI LILLY AND COMPANY (US) 2012-05-08 — — US disclosed
US-8173821-B2 Serotonin and norepinephrine reuptake inhibitor ELI LILLY AND COMPANY (US) 2012-05-08 — — US disclosed
US-8173821-B2 Serotonin and norepinephrine reuptake inhibitor ELI LILLY AND COMPANY (US) 2012-05-08 — — US disclosed
WO-2010117979-A2 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — WO disclosed
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — US disclosed
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — US disclosed
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR ELI LILLY AND COMPANY (US) 2010-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261762-A1 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR SLC6A2, SLC6A4, TPH1 SSTR4 339/4885GPR119 708/4885TP53 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback